Loading clinical trials...
Loading clinical trials...
An Parallel Phase II Study of Tarceva (Erlotinib) in Patients With Advanced Non-small Cell Lung Cancer (Stage IIIB/IV) Not Pre-treated by Chemotherapy Including Dose Escalation to Toxicity in Current and Former Smokers
Conditions
Interventions
erlotinib [Tarceva]
Locations
11
France
Marseille, France
Villejuif, France
Hamburg, Germany
Milan, Italy
Rozzano, Italy
Amsterdam, Netherlands
Start Date
September 1, 2006
Primary Completion Date
October 1, 2010
Completion Date
October 1, 2010
Last Updated
December 19, 2014
NCT06305754
NCT07190248
NCT07100080
NCT07195695
NCT06357533
NCT06731413
Lead Sponsor
Hoffmann-La Roche
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions